PURPOSE: To evaluate the effect of complete intrastromal corneal ring implantations on patients with pellucid marginal degeneration (PMD). DESIGN: Prospective interventional case series. PATIENTS AND METHODS: Thirty-three eyes with PMD were included into the study. After pocket creation with femtosecond laser (Femtec; 20/10 PerfectVision), MyoRing implantation was performed. Uncorrected and corrected distance visual acuity (UDVA, CDVA), subjective refraction, keratometry, central corneal thickness, corneal biomechanical profile (Ocular Response Analysis), and whole-eye wavefront aberrometry (iTrace) were evaluated preoperatively and also postoperatively, 1 month, 3 months, 6 months, and 1 year after the operation. RESULTS: One month after surgery, significant improvements were observed in UDVA (ANOVA; P=0.02), mean keratometry, sphere (ANOVA; P <0.001), and cylinder (ANOVA; P=0.04) with no significant changes afterwards. No significant change occurred in the corneal biomechanical profile. Primary coma and trefoil reduced after 1 year (ANOVA; P values were 0.02 and 0.06, respectively). Primary spherical aberration significantly increased according to the 1-year follow-up (ANOVA; P<0.001). No significant complication was observed. CONCLUSION: MyoRing is considered as a treatment modality for spherocylindrical correction in patients with PMD, with an acceptable safety and efficacy profile.
PURPOSE: To evaluate the effect of complete intrastromal corneal ring implantations on patients with pellucid marginal degeneration (PMD). DESIGN: Prospective interventional case series. PATIENTS AND METHODS: Thirty-three eyes with PMD were included into the study. After pocket creation with femtosecond laser (Femtec; 20/10 PerfectVision), MyoRing implantation was performed. Uncorrected and corrected distance visual acuity (UDVA, CDVA), subjective refraction, keratometry, central corneal thickness, corneal biomechanical profile (Ocular Response Analysis), and whole-eye wavefront aberrometry (iTrace) were evaluated preoperatively and also postoperatively, 1 month, 3 months, 6 months, and 1 year after the operation. RESULTS: One month after surgery, significant improvements were observed in UDVA (ANOVA; P=0.02), mean keratometry, sphere (ANOVA; P <0.001), and cylinder (ANOVA; P=0.04) with no significant changes afterwards. No significant change occurred in the corneal biomechanical profile. Primary coma and trefoil reduced after 1 year (ANOVA; P values were 0.02 and 0.06, respectively). Primary spherical aberration significantly increased according to the 1-year follow-up (ANOVA; P<0.001). No significant complication was observed. CONCLUSION: MyoRing is considered as a treatment modality for spherocylindrical correction in patients with PMD, with an acceptable safety and efficacy profile.
Authors: Nienke Visser; Tos T J M Berendschot; Noël J C Bauer; Rudy M M A Nuijts Journal: Invest Ophthalmol Vis Sci Date: 2012-04-06 Impact factor: 4.799
Authors: Jordana Sandes; Larissa R S Stival; Marcos Pereira de Ávila; Paulo Ferrara; Guilherme Ferrara; Leopoldo Magacho; Luana P N Araújo; Leonardo Torquetti Journal: Int J Ophthalmol Date: 2018-05-18 Impact factor: 1.779